Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.003% AR-15512 in Dry Eye Disease
NCT06544694Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acoltremon in dry eye disease (DED), sponsored by Alcon Inc.. Started Oct 2024; status: completed.
02
Drugs
acoltremon
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06544694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544694.